Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel <i>R-Spondin2</i> RNA Fusion and <i>NTRK3</i> Mutation

Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a Novel <i>R-Spondin2</i> RNA Fusion and <i>NTRK3</i> Mutation

Ampullary adenocarcinoma is a rare malignancy that lacks standard systemic treatment. We describe a case of recurrent metastatic ampullary adenocarcinoma of the pancreaticobiliary subtype treated with nanoparticle albumin-bound (nab)-paclitaxel and gemcitabine as first-line treatment. This report al...

Full description

Bibliographic Details
Main Authors: Maryknoll P. Linscott, Havell Markus, Mackenzie Sennett, Catherine Abendroth, Nelson S. Yee
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Biomedicines
Subjects:
ampullary adenocarcinoma
pancreaticobiliary
nab-paclitaxel
gemcitabine
molecular profiling
circulating tumor DNA
Online Access:https://www.mdpi.com/2227-9059/11/8/2326

Internet

https://www.mdpi.com/2227-9059/11/8/2326

Similar Items